IP Library › Granted Patent US 11,197,826
Granted Patent B2
US 11,197,826 · App. 16/065,468 · Granted Dec 14, 2021

Oil-in-water emulsions including retinoic acid

Inventors: Ugo D'Oro (Vienna, IT); Luis Brito (Cambridge, MA); Derek O'Hagan (Camridge, MA); Silvia Vendetti (Rome, IT)
Assignee: NOVARTIS AG
A61K9/1075A61K9/0019A61K9/107A61K31/203A61K39/39A61K45/06A61K47/06A61K47/22A61M5/178A61K2039/55511A61K2039/55566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,197,826
App. No.
16/065,468
Granted
Dec 14, 2021
Kind
B2
Abstract

Retinoic acid, or an analogue thereof, is delivered within an oil-in-water emulsion to provide an improved immunological adjuvant.

Claims (6)

1. An oil-in-water emulsion including squalene; polysorbate 80; sorbitan trioleate and retinoic acid, wherein at least 80% (by number) of the emulsion's oil droplets are less than 220 nm in diameter and wherein the oil-in-water emulsion has 4-6% by volume squalene; 0.4-0.6% by volume polysorbate 80; 0.5% ±0.05 by volume sorbitan trioleate; and the retinoic acid is present at a concentration between 2 μg/mL to 2 mg/mL.

2. The oil-in-water emulsion of claim 1 , wherein the emulsion is injectable.

3. An immunogenic composition comprising (i) the oil-in-water emulsion of claim 1 , and (ii) at least one immunogen.

4. The oil-in-water emulsion of claim 1 , wherein the retinoic acid is all-trans retinoic acid.

5. The oil-in-water emulsion of claim 1 , wherein the emulsion does not contain one or more of oleic acid butylated hydroxytoluene, lecithin, medium-chain triglycerides, soybean oil, and/or cetyl palmitate.

6. The immunogenic composition of claim 3 , wherein the retinoic acid is all-trans retinoic acid.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 069642/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: BRITO, LUIS; O'HAGAN, DEREK
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 057368/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: VENDETTI, SILVIA
To: ISTITUTO SUPERIORE DI SANITA
Reel/Frame 057369/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: D'ORO, UGO
To: GSK VACCINES S.R.L.
Reel/Frame 057368/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: GSK VACCINES S.R.L.
To: NOVARTIS AG
Reel/Frame 057370/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS AG
Reel/Frame 057370/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: ISTITUTO SUPERIORE DI SANITA
To: GSK VACCINES S.R.L.
Reel/Frame 057370/0001 →
Priority Claims (1)
EP 15202332 · Dec 23, 2015 · regional
Continuity (1)
Related Publication 20190083397A1 · Mar 21, 2019